Marquant Michael, Gessler Simon, Diechtierow Michael, Gerber Julia, Adar Née Oeztuerk Zekiye
Roche Diagnostics GmbH, Mannheim, Germany.
Roche Diagnostics International Ltd, Rotkreuz, Switzerland.
J Diabetes Sci Technol. 2025 May 31:19322968251319344. doi: 10.1177/19322968251319344.
Point-of-care (POC) strip-based blood glucose monitoring systems (BGMSs) used by health care professionals must be more robust than those used for patient self-testing, due to a higher likelihood of BG interferents present in the blood of hospitalized patients. The Cobas® Pulse system (Roche Diagnostics GmbH, Mannheim, Germany) is a novel strip-based POC BGMS designed for multiple patient use in professional health care environments. We report a series of experiments evaluating the effects of several potential interferents, and of extreme conditions, on the BGMS's performance.
Blood samples were spiked with glucose and various potential interferents or tested at extreme environmental conditions. Studies were performed using three lots of Cobas glucose test strips (Roche Diagnostics GmbH, Mannheim, Germany). Interference results over all test strip lots are expressed as the absolute or relative mean bias between test and control.
Compared with control, the mean absolute or relative bias did not exceed ±10 mg/dL or ±10% for any endogenous substance or drug tested, any combination of hematocrit level or glucose concentration over the ranges tested, or any test at altitudes up to 4300 m above sea level, with any of the three test strip lots. Varying oxygen concentrations (partial pressure) in a blood sample did not affect glucose measurements. All interference results were within the specified accuracy limits. Contamination of blood samples with skin disinfectants, extreme levels of ascorbic acid, or hematocrit levels outside the claimed range did not cause wrong test results.
POC BGMS performance was not altered by interfering substances after a rigorous evaluation under a wide range of conditions.
由于住院患者血液中存在血糖干扰物的可能性更高,医疗保健专业人员使用的即时检测(POC)试纸条式血糖监测系统(BGMS)必须比患者自我检测使用的系统更强大。Cobas® Pulse系统(德国曼海姆罗氏诊断有限公司)是一种新型的试纸条式POC BGMS,设计用于专业医疗环境中的多名患者使用。我们报告了一系列实验,评估了几种潜在干扰物以及极端条件对BGMS性能的影响。
向血样中添加葡萄糖和各种潜在干扰物,或在极端环境条件下进行测试。使用三批Cobas血糖测试条(德国曼海姆罗氏诊断有限公司)进行研究。所有测试条批次的干扰结果表示为测试值与对照值之间的绝对或相对平均偏差。
与对照相比,对于所测试的任何内源性物质或药物、在所测试范围内血细胞比容水平或葡萄糖浓度的任何组合、或在海拔高达4300米的任何测试中,使用三批测试条中的任何一批,平均绝对或相对偏差均未超过±10 mg/dL或±10%。血样中不同的氧气浓度(分压)不会影响葡萄糖测量。所有干扰结果均在规定的准确度范围内。皮肤消毒剂污染血样、极高水平的抗坏血酸或超出声称范围的血细胞比容水平均未导致错误的测试结果。
在广泛条件下进行严格评估后,干扰物质并未改变POC BGMS的性能。